On September 9, 2019 CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reported that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company at the 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. on Tuesday, September 10, 2019 in New York, NY (Press release, Cytosorbents, SEP 9, 2019, https://www.prnewswire.com/news-releases/cytosorbents-to-present-at-the-hc-wainwright-21st-annual-global-investment-conference-300913899.html [SID1234539391]). Both Dr. Chan and Chief Financial Officer, Kathleen Bloch will meet with investors in 1×1 meetings during the conference on September 9-10, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co.
Where: Lotte New York Palace, 455 Madison Ave, New York, NY
When: Tuesday, September 10, 2019 from 4:40-5:05PM EDT
Room: Holmes II
Webcast: 21st Annual Global Investment Conference Webcast Link

A live webcast of the presentation will be available at the above webcast link. An archived replay of the webcast will be available for 90 days following the event.

On September 9, 2019 KAHR Medical, a biopharmaceutical company developing a novel drug platform based on bi-functional, immunotherapeutic fusion proteins known as DSP (Dual Signaling Proteins), reported a new clinical collaboration with Roche (Press release, KAHR Medical, SEP 9, 2019, View Source [SID1234539390]). The collaboration will explore KAHR’s lead program, DSP107, a SIRPα-41BBL DSP, in combination with Roche’s PD-L1-blocking checkpoint inhibitor (CPI) atezolizumab (Tecentriq) in patients with advanced NSCLC who are refractory to checkpoint inhibitors. KAHR expects to file an Investigational New Drug (IND) application with the U.S. Food Drug Administration (FDA) and begin a Phase I/II trial in H1 2020 to evaluate DSP107 as a monotherapy and in combination with atezolizumab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are extremely pleased to collaborate with Roche to study the potential of atezolizumab in combination with DSP107, our lead drug candidate," said Yaron Pereg, PhD, CEO, KAHR Medical. "The combined approach of DSP107 alongside immune-checkpoint inhibition has already shown promise in preclinical studies. We look forward to examining the potential of DSP107 with atezolizumab in treating NSCLC patients with limited treatment options."

DSP107 targets CD47-overexpressing tumors, simultaneously blocking macrophage inhibitory signals and delivering an immune costimulatory signal to tumor antigen-specific activated T-cells. CD47 is overexpressed on many cancer cells and binds SIRPα on immune phagocytic cells to produce a "don’t eat me" signal. DSP107 binds CD47 on cancer cells, blocking interaction with SIRPα and thus blocking the "don’t eat me signal". Simultaneously, DSP107 binds 41BB on T-cells, stimulating their activation. These activities lead to targeted immune activation through both macrophage and T-cell mediated tumor destruction. In combination with atezolizumab, DSP107 has the potential to enhance anti-tumor immune response.

The planned Phase I/II study will evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of DSP107 in advanced solid tumors. The preliminary efficacy of both DSP107 monotherapy and combination therapy with atezolizumab will be evaluated in patients with advanced NSCLC who are refractory to PD-1/PD-L1 inhibitors. KAHR will be the sponsor of the study and Roche will provide the clinical supply of atezolizumab.

On September 9, 2019 Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI;OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, reported that Jesse Ledger, Nuvo’s President & Chief Executive Officer will present at the H.C. Wainwright 21st Annual Global Investment Conference to be held September 8-10, 2019 in New York City (Press release, Nuvo Pharmaceuticals, SEP 9, 2019, https://www.prnewswire.com/news-releases/nuvo-pharmaceuticals-update-to-nuvos-presentation-time-at-hc-wainwright-global-investment-conference-300913789.html [SID1234539389]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Updated Nuvo Presentation Details

Date:

Tuesday, September 10, 2019

Time:

4:15 p.m. ET (previously announced time 5:00 p.m. ET)

Location:

Lotte New York Palace Hotel

A link to the live audio webcast of the presentation will be available on the Home Page of the Company’s website at www.nuvopharmaceuticals.com. The archived webcast will be available for 30 days.

Mr. Ledger will be available during the conference for one-on-one meetings. Members of the investment community who are interested in meeting with the Company should contact conference coordinators to arrange an appointment or contact Nuvo directly via email at [email protected].

On September 9, 2019 Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, reported that the Company will present at the upcoming Annual CAR-TCR Summit in Boston, MA September 10-13, 2019 (Press release, Cellular Biomedicine Group, SEP 9, 2019, View Source [SID1234539388]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wednesday, September 11, 2:47pm
Yihong Yao, PhD, Chief Scientific Officer
"Meeting the Challenge of Delivering Cell & Gene Therapy Products to Patients in China"

Medical digitalization will fundamentally transform research, clinical, and healthcare as a whole
How China can advance the progress in novel therapy modalities
De-risking clinical trials by leveraging fast-track clinical studies
A copy of the presentation will be made available on the Company’s website following the presentation.

On September 9, 2019 Jubilant Life Sciences Limited has reported that Dr. Syed Kazmi, PhD, MBA, will join its new innovative biopharmaceutical company in the U.S., Jubilant Therapeutics Inc., as President and Chief Executive Officer (Press release, Jubilant Life Sciences, SEP 9, 2019, View Source;jubilant-therapeutics-inc-300914090.html [SID1234539387]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Kazmi joins from Novartis Pharmaceuticals Corporation where he was Vice President, Global Head of Business Development & Licensing for Oncology.

Earlier this year, Jubilant Life Sciences spun off select proprietary innovation assets that are in various stages of discovery and development into Jubilant Therapeutics. The new company has a unique business model with a combination of semi-virtual set up and significant synergies with rest of Jubilant Life Sciences including strategic partnership with Jubilant Biosys, a world-class preclinical CRO.

Jubilant Therapeutics’ strategy is to discover and develop novel small molecule modulators of important and previously undruggable targets primarily in oncology and establish creative partnerships to bring innovative therapeutics to patients in need.

The Company’s current pipeline includes a novel dual epigenetic inhibitor of LSD1/HDAC6 to address unmet needs in liquid cancers like acute myeloid leukemia (AML), a small molecule PDL-1 therapy with comparable efficacy to large molecules and lower side effects, a small molecule PAD4 inhibitor with potential to address unmet needs in multiple auto-immune disorders and a PRMT5 inhibitor for lymphoma.

"We extend a warm welcome to Syed as the CEO of Jubilant Therapeutics," said Shyam Bhartia and Hari Bhartia, Chairman and Co-Chairman of Jubilant Life Sciences. "Syed has had an accomplished career of over 25 years in M&A, licensing, strategic collaborations, and R&D in both specialty biotech and large pharma companies. We are confident that his extensive experience will help make Jubilant Therapeutics a successful global clinical stage biopharmaceutical company with the mission of transforming the lives of patients with serious diseases."

"I am honored to join as CEO to continue building the pipeline assets and collaborations to fast-track new innovative drugs to market. I look forward to growing Jubilant Therapeutics into a first-in-class biopharma company," said Syed Kazmi.